RxDoctor Payments Data

Erika Herrera, DO

Family Medicine · Knoxville, TNNPI 1043716368

Payments from drug & device makers

$6,129in general payments, 2019–2025

Across 368 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$629
  • Otsuka America Pharmaceutical, Inc.$582
  • GSK$560
  • Pfizer$453
  • Amgen$374
  • plus $3K from 30 others

What the payments were for

  • Food & beverage$6,03999%
  • Education$901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,129 in reported general payments places this provider in the 80th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$92,788
Medicare patients
120
Services billed
3,438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter131$107,152
JardianceEmpagliflozin72$102,395
OzempicSemaglutide68$78,593
EliquisApixaban53$58,801
MounjaroTirzepatide39$43,298
FarxigaDapagliflozin Propanediol21$17,598
RybelsusSemaglutide12$16,409
Repatha SureclickEvolocumab12$11,931
ArexvyRsvpref3 Antigen/As01e/Pf32$10,029
ShingrixVaricella-Zoster Ge/As01b/Pf29$6,595
JanuviaSitagliptin Phosphate11$6,519
Atorvastatin Calcium379$2,990
Albuterol Sulfate HfaAlbuterol Sulfate83$2,835
Potassium Chloride61$2,351
Levothyroxine Sodium169$1,629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Arexvy, Shingrix$560$123,777192 claims
Boehringer IngelheimJardiance$65$102,39572 claims
Novo NordiskOzempic, Rybelsus$1,015$95,00280 claims
PfizerEliquis$453$58,80153 claims
Lilly USA, LLCMounjaro$255$43,29839 claims
AstraZenecaFarxiga$343$17,59821 claims
MerckJanuvia$11$6,51911 claims
AbbVieSynthroid$629$57714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →